Arvinas Reports $249.7 Million Revenue in Q2 2026, Significant Net Income Turnaround

Arvinas, Inc. reported significant financial growth in its latest quarterly filing, with revenues reaching $249.7 million for the three months ended June 30, 2026, compared to just $22.4 million in the same period last year. This increase of $227.3 million was primarily driven by the recognition of $126.4 million in deferred revenue following the company's Rigel License Agreement, alongside a $50 million milestone payment related to the FDA approval of its product VEPPANU. For the six months ending June 30, 2026, total revenue was $265.3 million, up from $211.2 million in the prior year, marking a $54.1 million increase.

Operating expenses for the second quarter of 2026 totaled $85.6 million, a decrease from $93.9 million in the same quarter of 2025. This reduction was largely attributed to lower research and development costs, which fell to $52.6 million from $68.6 million year-over-year. General and administrative expenses also saw a slight decline, totaling $24 million compared to $25.3 million in the previous year. The company reported a net income of $169.4 million for the second quarter, a substantial turnaround from a net loss of $61.2 million in the same period last year.

Strategically, Arvinas has made significant advancements, including the FDA approval of VEPPANU, the first PROTAC protein degrader approved for use in treating advanced breast cancer. The company entered into a licensing agreement with Rigel Pharmaceuticals, granting Rigel exclusive rights for the development and commercialization of VEPPANU. This agreement includes a $70 million upfront payment and potential future milestone payments totaling up to $320 million, along with tiered royalties based on sales.

Operationally, Arvinas has streamlined its workforce, reducing headcount by 15% to optimize costs and align with its strategic goals. The company is also advancing multiple clinical programs, including ARV-393, ARV-102, ARV-027, and ARV-806, which target various cancers and neurodegenerative diseases. As of June 30, 2026, Arvinas reported cash, cash equivalents, and marketable securities totaling approximately $567.9 million, which it believes will fund operations into the second half of 2028.

Looking ahead, Arvinas remains focused on its clinical development pipeline and expects to continue incurring operating losses as it advances its product candidates. The company acknowledges the inherent risks in drug development and the need for additional funding to support its ongoing operations and future growth.